All In Biotech

Free tool

FAERS Monitor: Vocabria

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212887 or its brand name (Vocabria, Cabotegravir Sodium). Reports on generic versions are filed under their own applications.

Reports

1,605

Serious

1,144

71% of reports

Hospitalization

219

Death reported

89

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • viral load increased110
  • injection site pain109
  • product dose omission issue89
  • virologic failure66
  • hepatitis b65
  • off label use64
  • pathogen resistance61
  • nausea58
  • fatigue57
  • headache56
  • inappropriate schedule of product administration56
  • hepatitis b reactivation54
  • rash52
  • malaise49
  • blood hiv rna increased48

Reports by year received

View as table
YearReports
20162
20172
20193
20202
202182
2022339
2023364
2024313
2025330
2026168

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,554 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
viral load increasedSignal110382.1318.240,267
blood hiv rna increasedSignal48356.3268.616,215
hepatitis b reactivationSignal54226.8174.111,714
virologic failureSignal66162.8128.410,328
hepatitis bSignal65142.9112.58,922
pathogen resistanceSignal6188.369.05,145
injection site painSignal1094.73.9314
inappropriate schedule of product administrationSignal564.13.1128
product dose omission issueSignal894.03.2197
rash521.61.210
malaise491.51.17
headache561.20.91
nausea581.00.70
fatigue571.00.70
off label use641.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.